Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

U.S. State Attorneys General Probe Opioid Drug Companies

By Nate Raymond (Reuters) | on June 27, 2017 | 0 Comment
Latest News
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

A bipartisan group of state attorneys general has announced that they are jointly investigating the marketing and sales practices of drug companies that manufacture opioid painkillers at the center of a national addiction epidemic.

You Might Also Like
  • U.S. State, Local Government Lawsuits over Opioids Face Uphill Battle
  • Mallinckrodt Settles U.S. Opioid Drug Probe for $35 Million
  • U.S. Senator Launches Probe into Five Top Opioid Drugmakers

Attorneys general from states including Massachusetts, Texas, Illinois and Pennsylvania announced the investigation two weeks after Ohio Attorney General Mike DeWine sued five drug manufacturers for misrepresenting the risks of opioids.

“We are looking into what role, if any, marketing and related practices might have played in the increasing prescription and use of these powerful and addictive drugs,” District of Columbia Attorney General Karl Racine, a Democrat, said in a statement.

It was unclear exactly how many states are involved in the probe, though officials said a majority of attorneys general are part of the coalition. Among those leading the probe is Tennessee Attorney General Herbert Slatery, a Republican. Officials did not specify which companies were under investigation.

Opioid drugs, including prescription painkillers and heroin, killed more than 33,000 people in the United States in 2015, more than any year on record, according to the U.S. Centers for Disease Control and Prevention.

Separate lawsuits by attorneys general in Ohio and Mississippi, the two states that have pursued opioid-related cases to date, have targeted Purdue Pharma LP, Johnson and Johnson, Endo International Plc, Teva Pharmaceutical Industries Ltd and Allergan Plc.

Teva in a statement said it is “committed to the appropriate promotion and use of opioids.” Representatives for the other companies did not immediately respond to requests for comment.

The companies have denied wrongdoing, saying the U.S. Food and Drug Administration approved their products as safe and effective and saying that they carried warning labels that disclosed their risks.

In announcing his office’s lawsuit on May 31, Ohio Attorney General DeWine said the drug companies helped unleash the crisis by spending millions of dollars marketing and promoting such drugs as Purdue’s OxyContin.

The lawsuit said the drug companies disseminated misleading statements about the risks and benefits of opioids as part of a marketing scheme aimed at persuading doctors and patients that drugs should be used for chronic rather than short-term pain.

Similar lawsuits have been filed by local governments, including two California counties, the cities of Chicago, Illinois and Dayton, Ohio, three Tennessee district attorneys, and nine New York counties.

Topics: AddictionAttorney GeneralCDCDeathDrug AbuseepidemicLawsuitMortalityOhioOpioidsOxycontinPainkillerPharmaceutical CompaniesRiskState

Related

  • A Malpractice Lawsuit Gives Emergency Physician Lifelong Lessons

    May 9, 2024 - 0 Comment
  • Uncovering Hidden ACEP Member Resource Gems

    May 9, 2024 - 0 Comment
  • How to Manage Elderly Patient Pain without Opioids

    February 13, 2024 - 0 Comment

Current Issue

ACEP Now May 03

Read More

No Responses to “U.S. State Attorneys General Probe Opioid Drug Companies”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*


Current Issue

ACEP Now May 03

Read More

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603